Almirall, S.A. is a Spanish pharmaceutical company specializing in medical dermatology, headquartered in Barcelona and founded in 1944. It focuses on researching, developing, manufacturing, and marketing innovative medicines to address unmet needs in skin health, particularly for conditions like psoriasis, atopic dermatitis, acne, actinic keratosis, and onychomycosis. With a portfolio exceeding 140 products distributed in over 100 countries through 15 affiliates and partnerships, Almirall leads Europe in medical dermatology, generating €898.8 million in total revenues in 2023 from approximately 1,904 employees. Key products include Ilumetri (tildrakizumab) for psoriasis, Ebglyss (lebrikizumab) for atopic dermatitis, Wynzora (calcipotriol/betamethasone) for psoriasis, Klisyri (tirbanibulin) for actinic keratosis, and Seysara (sarecycline) for acne. The company invests around 12% of net sales in R&D, supported by centers in Spain and Germany, and collaborates with global institutions like Imperial College London and the NIH to advance therapies such as mRNA-based dermatology treatments. Almirall's strategic shift to dermatology since 2013, bolstered by acquisitions like Hermal, Aqua Pharmaceuticals, and Poli Group, underscores its role in transforming patient lives through scientific innovation and global reach.